Omisirge Market Report 2026

Omisirge Market Overview

• The Omisirge market growth in the historic period has been driven by increasing incidence of hematologic malignancies, limitations of conventional cord blood transplantation • Market expansion is supported by expansion of personalized cell therapy pipelines, rising investments in regenerative medicine • Growth Driver: Rising Demand For Personalized Treatments Driving Growth In The Market • Market Trend: Technological Advancements Enhancing Transplant Efficiency And Patient Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Omisirge Market?

Omisirge is an advanced cell therapy used in allogeneic hematopoietic stem cell transplantation (HSCT) for patients with blood cancers or disorders. It is derived from umbilical cord blood and designed to expedite neutrophil recovery, reducing the risk of infection and complications after transplantation. Omisirge contains expanded hematopoietic progenitor cells (CD34+ cells) cultured to enhance their number and functionality, enabling faster engraftment compared to standard cord blood transplantation. The main types of indications for omisirge include leukemia, lymphoma, myeloma, and others. Leukemia is a type of cancer that affects the blood and bone marrow, leading to the production of abnormal white blood cells. It is distributed through both direct sales and distributors and is used by hospitals and clinics, and ambulatory surgical centers.

What Is The Omisirge Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of personalized cell therapy pipelines, rising investments in regenerative medicine, increasing adoption of advanced transplantation protocols, growing focus on reducing post-transplant complications, expansion of cell therapy manufacturing infrastructure. Major trends in the forecast period include increasing adoption of expanded cord blood therapies, rising use of ex vivo cell expansion techniques, growing focus on faster neutrophil engraftment, expansion of allogeneic hsct applications, enhanced manufacturing scalability for cell therapies.

Global Omisirge Market Segmentation

1) By Clinical Indication: Leukemia, Lymphoma, Myeloma, Other Hematologic Malignancies 2) By Distribution Channel: Direct Sales, Distributors 3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers

What Is The Driver Of The Omisirge Market?

The increasing demand for personalized treatments is expected to propel the growth of the omisirge market going forward. Personalized treatments are medical interventions tailored to an individual's specific genetic, environmental, and lifestyle factors to optimize effectiveness and minimize side effects. The demand for personalized treatments is rising due to advancements in genetic research, increased awareness of individualized healthcare, and the growing recognition that tailored therapies offer improved efficacy and fewer side effects compared to traditional one-size-fits-all approaches. Omisirge enhances personalized treatments by leveraging its ability to adapt to individual patient needs, targeting specific immune responses, and optimizing therapeutic outcomes based on the unique characteristics of each patient's cancer profile.For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, the increasing demand for personalized treatments is expected to drive the growth of the omisirge industry.

Key Players In The Global Omisirge Market

Major companies operating in the omisirge market are Gamida Cell Ltd.

Global Omisirge Market Trends and Insights

Major companies operating in the Omisirge market are focusing on developing technological advancements, such as omidubicel-onlv, to enhance transplant efficiency and improve patient recovery outcomes. Omidubicel-onlv is an allogeneic, stem-cell–based therapy derived from umbilical cord blood and engineered to enhance cell expansion for faster engraftment. For instance, in May 2023, the U.S. Food and Drug Administration, a US-based federal agency, approved Gamida Cell’s product Omisirge, which aims to improve stem cell engraftment and reduce infection risks in transplant patients. The FDA approval of Omisirge introduced an enhanced, expanded cord-blood–derived cell therapy designed to accelerate neutrophil recovery and lower infection risk in patients with hematologic malignancies. It offers a more reliable engraftment profile compared to traditional cord blood, making transplants faster and clinically safer.

What Are Latest Mergers And Acquisitions In The Omisirge Market?

In March 2025, Ayrmid Pharma Ltd., a U.S.-based cell therapy company specializing in nicotinamide-enhanced allogeneic progenitor cell therapies, partnered with RoslinCT to advance manufacturing capabilities and support the scalable production of its cell therapy programs. With this partnership, Ayrmid secures a dual sourcing strategy to ensure a stable, commercial-scale supply of Omisirge (omidubicel-only) by transferring the technology and enabling RoslinCT’s Hopkinton, Massachusetts, facility to manufacture the product, thereby enhancing its manufacturing capacity and supply reliability. RoslinCT is a Scotland-based contract development and manufacturing organization (CDMO) providing process development, analytical services, and GMP manufacturing for advanced cell and gene therapies.

Regional Insights

North America was the largest region in the omisirge market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Omisirge Market?

The omisirge market consists of sales of cell therapy products, gene therapy products, cord blood-derived products, and tissue engineering products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Omisirge Market Report 2026?

The omisirge market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the omisirge industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.